Exosome IV protocols

I write this page partly because the IV protocol is the most under-explained component of Korean regenerative practice, and partly because the under-explanation is by design. A clinic that sells you an exosome infusion without disclosing the dose, the source, and the frequency is selling you an experience, not a treatment. The serious Myeongdong clinics — and the more rigorous Gangnam ones — disclose all three without prompting; the others mumble. This is the technical page in the archive, written for readers who want to read the consent form properly before signing it. It assumes some clinical literacy and does not apologise for the assumption. If you are early in your research, the overview page is a softer entry point; if you are deciding between two specific clinics on a Wednesday in Seoul, this is the page that will help you tell them apart. The framework: dosing is conventionally expressed in particles per millilitre or in vesicle protein content, and the range across Korean products spans roughly two orders of magnitude; frequency is conventionally weekly or fortnightly across a course; and source is the variable that separates allogeneic from autologous and matters more for safety, regulation, and clinical effect than the marketing copy suggests. The MFDS regulates the allogeneic Korean products as cell-derived biologics with batch tracking; the autologous pathway runs differently and is, in current practice, almost never what international visitors actually receive. I will walk through each variable, explain what the typical Myeongdong clinic actually administers, and flag the disclosure points that distinguish a serious protocol from an opaque one.

Dosing: particles, protein, and the gap between them

Exosome dose is reported, depending on the manufacturer, in one of two units. Particle count — typically expressed as particles per millilitre, in the range of 10^9 to 10^11 — captures the number of vesicles delivered. Vesicle protein content — typically expressed in micrograms or milligrams — captures the cumulative cargo mass. The two correlate but are not identical; a vesicle population can be high in count and low in protein density, or vice versa, depending on the harvest conditions. The serious manufacturers report both; the casual ones report neither and substitute marketing language about "high concentration". A Myeongdong IV infusion conventionally delivers between one and five billion exosomes per session, depending on the formulation and the clinical indication. Higher dose is not automatically better — there are diminishing returns and, at very high concentrations, signal-noise issues that may reduce clinical effect. The patient-facing question is not what the highest dose available is; it is whether the dose is documented and whether the documentation is consistent across sessions in a course.

Frequency: weekly, fortnightly, or one-and-done

Course structure varies more than the marketing suggests. The most common Myeongdong protocol runs four to six weekly IV infusions across a four-to-six-week course, with maintenance every three to six months thereafter. A compressed course for international visitors compresses this into two infusions across a single seven-day trip plus a return trip three months later — clinically reasonable, given the half-life of the systemic effect, but worth confirming up front. A one-and-done protocol — a single infusion with no follow-up — is sometimes marketed for short-stay visitors and is, in my editorial reading, a marketing convenience rather than a clinical protocol. The exosome systemic effect peaks at roughly two to four weeks post-infusion and decays across the following two to three months; a single dose has measurable effect, but the cumulative effect from a course is meaningfully different. A serious clinic will explain this distinction; a tourist-calibrated clinic will sell you the convenience and let you draw your own conclusions about the half-life.

Allogeneic vs autologous: the source variable

This is the variable that matters most and is least often disclosed. Allogeneic exosomes are harvested from a third-party donor source — typically umbilical-cord mesenchymal stem cells (UC-MSCs) cultured in licensed Korean facilities under GMP conditions. The cells are not the patient's; the exosomes are produced at industrial scale, batch-tracked, and distributed to clinics as a finished product. The MFDS regulates this category as cell-derived biologics with formal approval pathways. Autologous exosomes are harvested from the patient's own cells — typically adipose-derived or PBMC-derived — and prepared on a per-patient basis, which is logistically complex and clinically distinct. Autologous protocols exist in Korea but are rare in mid-tier aesthetic practice; the practical question for a visiting patient is essentially never autologous-versus-allogeneic but rather which allogeneic product. The serious Korean manufacturers — and there are roughly half a dozen with meaningful market presence — disclose source tissue, donor screening, GMP certification, and MFDS approval reference. A clinic that cannot tell you which manufacturer's product they are administering is administering something they have not properly diligenced.

MFDS-approved allogeneic products in current Korean practice

I will not name specific products by brand because the regulatory landscape evolves and any list dates quickly; the MFDS public registry is the authoritative source and the editorial reference I default to. The patient-facing diligence: ask the clinic coordinator for the product name and the MFDS approval reference. Cross-check the reference against the MFDS public registry or, if you read Korean, the more granular Korean-language portal. Confirm the manufacturer's GMP certification status. Confirm batch traceability — the better Korean manufacturers stamp each vial with a lot number that allows post-market traceback if a safety event occurs. Where the manufacturer or product is not disclosed, treat the protocol as unverifiable and price the risk accordingly. Where the disclosure is forthcoming, the safety record of the MFDS-approved allogeneic exosome category is, on the published evidence to date, favourable — the dominant adverse events are mild, transient, and self-limiting (low-grade fever, fatigue, injection-site reaction in the case of microneedling delivery).

The infusion itself: what happens in the chair

Practically: a Myeongdong exosome IV runs thirty to forty-five minutes in a recliner chair, with the patient awake, phone-reading, occasionally with a saline pre-load and a normal-saline carrier. The exosomes are reconstituted from a lyophilised vial into a sterile saline drip, delivered through a peripheral IV line in the antecubital fossa. There is no general anaesthesia, no sedation, and no immediate downtime. Some patients report a feeling of warmth or mild flush in the first ten minutes; some report nothing at all. The post-infusion protocol is conventionally hydration (oral water across the rest of the day), no alcohol for at least 48 hours, and no intense exercise for 72 hours — the same protocol I cover in detail on the aftercare page. The systemic effect emerges across the following one to four weeks; the patient typically does not feel the infusion itself producing visible change in real time.

Microneedling delivery: the local complement to IV

Most Myeongdong protocols pair the IV with two to three microneedling sessions across the same course. The microneedling pen delivers exosome serum locally to the dermis through controlled needle channels, typically at depths of 0.5 to 2.0 millimetres calibrated to the treatment zone — shallower for under-eye and forehead, deeper for cheek and jaw. The local effect targets collagen and elastin synthesis in the papillary and reticular dermis, which the systemic IV reaches less directly. The combined protocol is more clinically robust than either modality alone; the IV alone risks under-delivery to the precise dermal depth where collagen synthesis happens, and the microneedling alone risks under-supplying the bio-active. A clinic that offers only one of the two modalities is not necessarily wrong but is offering a less complete protocol than the standard.

Senior physician oversight and consent

Korean medical practice requires physician oversight for IV infusion of cell-derived biologics; the actual line-placement and monitoring is conventionally performed by a registered nurse, with the senior physician reviewing the protocol and the patient pre-infusion. The international-patient diligence: confirm that the physician you consulted is the physician who will sign your protocol, not a name on the website who you do not actually meet. Confirm written consent that names the product, the dose, the frequency, and the manufacturer. Confirm that the consent form is in your working language, with translation where necessary — Korean-only consent for an international patient is a regulatory grey zone the Ministry of Health and Welfare has been increasingly explicit about, and a serious clinic does not require it.

“A clinic that sells you an exosome infusion without disclosing the dose, the source, and the frequency is selling you an experience, not a treatment.”

Frequently asked questions

What dose of exosomes does a typical Myeongdong IV deliver?

Between one and five billion exosomes per session, depending on the formulation and clinical indication. Higher dose is not automatically better; consistency of documented dose across sessions in a course matters more than absolute peak dose.

How often should I receive an exosome IV?

Conventionally four to six weekly infusions across a four-to-six-week course, with maintenance every three to six months. Compressed protocols for international visitors run two infusions across a single trip plus a return three months later. One-and-done is a marketing convenience rather than a clinical protocol.

What is the difference between allogeneic and autologous exosomes?

Allogeneic exosomes come from a third-party donor source — typically umbilical-cord mesenchymal stem cells cultured in licensed Korean facilities. Autologous exosomes come from the patient's own cells. Mid-tier Korean aesthetic practice almost universally administers allogeneic; autologous is rare in this segment.

Are the exosomes administered in Korean clinics MFDS-approved?

The MFDS regulates allogeneic exosome products as cell-derived biologics. Ask the clinic for the product name, manufacturer, and approval reference; cross-check against the MFDS public registry. A serious clinic discloses without hesitation.

What does an exosome IV feel like in the chair?

Thirty to forty-five minutes in a recliner, awake, phone-reading. Peripheral IV line in the antecubital fossa, sterile saline carrier, no anaesthesia or sedation. Some patients report mild warmth or flush in the first ten minutes; some report nothing.

What adverse events are reported in the published evidence?

The dominant reported events for MFDS-approved allogeneic exosomes are mild, transient, and self-limiting: low-grade fever, fatigue, and injection-site reaction in microneedling delivery. Serious adverse events are rare in the published Korean post-market surveillance.

Should I receive IV alone or IV plus microneedling?

IV plus microneedling is the more clinically complete protocol; the IV reaches the dermis less precisely than the microneedling delivery does, and the microneedling alone may under-supply the bio-active. The combined protocol is the standard.

What should the consent form say?

The product name, the manufacturer, the dose, the frequency, the senior physician's name, and the disclosed adverse-event profile. The form should be in your working language. Korean-only consent for an international patient is a regulatory grey zone a serious clinic does not require.